Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus MPI DTPA KIT CHELATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus MPI DTPA KIT CHELATE.
INDIUM IN-111 PENTETREOTIDE KIT vs MPI DTPA KIT - CHELATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical